Report #2844844

Received Jun 13, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Unknown
Age: Age unknown
State: GA
Recovered: Unknown
Vaccinated: Feb 14, 2025
Onset: Feb 14, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (HEPLISAV-B)	DYNAVAX TECHNOLOGIES CORPORATION	1	—	—

Symptoms (1)

Interchange of vaccine products

Symptom narrative

Received RECOMBIVAX as First Dose, and HEPLISAV-B as Second Dose; Initial report received on 12-May-2025. A pharmacist reported that a 43-year-old (gender, race, and ethnicity not reported) received HEPLISAV-B (hepatitis B vaccine) as the second dose for hepatitis B immunization after receiving RECOMBIVAX as the first dose of the series. No medical history or concomitant medications were reported. On 04-Jan-2025, the patient received dose 1 of a hepatitis B vaccine [RECOMBIVAX (lot #, expiration date, NDC #, route, and site not available)]. On 14-Feb-2025, 41 days after the receiving RECOMBIVAX, the patient received dose 2 of a hepatitis B vaccine [HEPLISAV-B (lot #, expiration date, NDC #, route, and site not available)]. No additional information was reported. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.